[
    [
        {
            "time": "2021-10-29",
            "original_text": "国产新冠疫苗迎“收获期”，龙头企业三季度业绩暴涨",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "收获期",
                    "龙头企业",
                    "三季度",
                    "业绩暴涨"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国产新冠疫苗迎“收获期”，龙头企业三季度业绩暴涨",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-29",
            "original_text": "智飞生物（300122）：主营增长依然强势 新冠海外销售期待突破",
            "features": {
                "keywords": [
                    "智飞生物",
                    "主营增长",
                    "新冠",
                    "海外销售",
                    "突破"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物（300122）：主营增长依然强势 新冠海外销售期待突破",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-29",
            "original_text": "国盛证券维持智飞生物买入评级：非新冠产品业绩贡献超预期，坚定看好公司未来发展",
            "features": {
                "keywords": [
                    "国盛证券",
                    "智飞生物",
                    "买入评级",
                    "非新冠产品",
                    "业绩贡献",
                    "超预期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "国盛证券维持智飞生物买入评级：非新冠产品业绩贡献超预期，坚定看好公司未来发展",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-29",
            "original_text": "华西证券：给予智飞生物买入评级",
            "features": {
                "keywords": [
                    "华西证券",
                    "智飞生物",
                    "买入评级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华西证券：给予智飞生物买入评级",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-29",
            "original_text": "智飞生物新冠疫苗等自研产品放量 助推净利润同比大增239.05%",
            "features": {
                "keywords": [
                    "智飞生物",
                    "新冠疫苗",
                    "自研产品",
                    "放量",
                    "净利润",
                    "同比大增"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物新冠疫苗等自研产品放量 助推净利润同比大增239.05%",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-29",
            "original_text": "智飞生物前三季度净利润大增239% 新冠疫苗成为增长主力",
            "features": {
                "keywords": [
                    "智飞生物",
                    "前三季度",
                    "净利润",
                    "大增",
                    "新冠疫苗",
                    "增长主力"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物前三季度净利润大增239% 新冠疫苗成为增长主力",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-29",
            "original_text": "操盘必读｜张坤加仓伊利减持泸州老窖，智飞生物三季度净增2倍！标普、纳指创新高",
            "features": {
                "keywords": [
                    "张坤",
                    "加仓",
                    "伊利",
                    "减持",
                    "泸州老窖",
                    "智飞生物",
                    "三季度",
                    "净增",
                    "标普",
                    "纳指",
                    "创新高"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "消费",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "操盘必读｜张坤加仓伊利减持泸州老窖，智飞生物三季度净增2倍！标普、纳指创新高",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-29",
            "original_text": "“中国民营疫苗第一股”重庆智飞生物前三个季度赚84亿元额增239% 股东数减筹码集中",
            "features": {
                "keywords": [
                    "中国民营疫苗第一股",
                    "重庆智飞生物",
                    "前三个季度",
                    "84亿元",
                    "额增",
                    "股东数减",
                    "筹码集中"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "“中国民营疫苗第一股”重庆智飞生物前三个季度赚84亿元额增239% 股东数减筹码集中",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]